MAPT and tauopathy: Our studies showed that TOMA treatment significantly attenuated retinal pathological changes, suggesting that tau immunotherapy could be potentially used to prevent vision loss in patients with tauopathy and improve their life quality considering that visual impairment, such as a decline in motion blindness, depth perception, color perception and contrast sensitivity, is common in AD patients [45].